This firm currently holds 3.73
M in liabilities with Debt to Equity (D/E) ratio of 0.31, which is about average as compared to similar companies. The company has a current ratio of 8.21, suggesting that it is liquid enough and is able to pay its financial obligations when due.
Our recommendation tool can cross-verify current
analyst consensus on Yield10 Bioscience and to analyze the firm potential to grow in the current economic cycle.
We determine the current worth of Yield10 Bioscience using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Yield10 Bioscience based exclusively on its
fundamental and basic
technical indicators. By analyzing Yield10 Bioscience's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of
Yield10 Bioscience's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Yield10 Bioscience. We calculate exposure to Yield10 Bioscience's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Yield10 Bioscience's related companies.
Watch out for price decline
Please consider monitoring Yield10 Bioscience on a daily basis if you are holding a position in it. Yield10 Bioscience is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Yield10 Bioscience stock to be traded above the $1 level to remain listed. If Yield10 Bioscience stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Yield10 Bioscience Investment Alerts
Yield10 investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Yield10 Bioscience performance across your portfolios.Please check all
investment alerts for Yield10
Yield10 Bioscience Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare Yield10 value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Yield10 Bioscience competition to find
correlations between indicators driving the intrinsic value of Yield10.
Yield10 Bioscience Gross Profit
Yield10 Bioscience Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Yield10 Bioscience previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Yield10 Bioscience Gross Profit growth over the last 10 years. Please check Yield10 Bioscience's
gross profit and other
fundamental indicators for more details.
What is driving Yield10 Bioscience Investor Appetite?
Yield10 Bioscience reported the previous year's revenue of 744
K. Net Loss for the year was (14.41
M) with loss before overhead, payroll, taxes, and interest of (4.04
M).
| 2015 | 2020 | 2021 (projected) |
Receivables | 388 K | 215.05 K | 220.71 K | Inventories | 379 K | 435.85 K | 447.32 K |
Margins Breakdown
Yield10 profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Yield10 Bioscience itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Yield10 Bioscience profit margins.
| Operating Margin | 7.62 |
| EBITDA Margin | 10.36 |
| Gross Margin | 37.45 |
| Profit Margin | 7.67 |
Yield10 Bioscience Earnings Before Interest Taxes and Depreciation Amortization USD is increasing over the last 8 years. The latest value of Yield10 Bioscience Earnings Before Interest Taxes and Depreciation Amortization USD is -10,157,103. Yield10 Bioscience Net Income Per Employee is decreasing over the last 8 years. Furthermore, Yield10 Bioscience Revenue Per Employee is decreasing over the last 8 years. Yield10 Bioscience Earnings Before Interest Taxes and Depreciation Amortization USD is increasing over the last 8 years. Yield10 Bioscience Net Income Per Employee is decreasing over the last 8 years. Furthermore, Yield10 Bioscience Revenue Per Employee is decreasing over the last 8 years.
Will Yield10 Bioscience latest rise continue?
Yield10 Bioscience latest mean deviation surges over 6.86. Yield10 Bioscience is displaying above-average volatility over the selected time horizon. Investors should scrutinize Yield10 Bioscience independently to ensure intended market timing strategies are aligned with expectations about Yield10 Bioscience volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Yield10 Bioscience's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Yield10 Bioscience's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Conclusion on Yield10 Bioscience
Whereas few other entities within the agricultural inputs industry are still a little expensive, even after the recent corrections, Yield10 Bioscience may offer a potential longer-term growth to institutional investors. To summarize, as of the 13th of March 2021, our analysis shows that Yield10 Bioscience barely shadows the market. The company is
undervalued and projects
high chance of distress for the next 2 years. However, our latest 30 days buy-sell recommendation on the company is
Strong Sell.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Yield10 Bioscience. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
